MétaCan
Menu
← Back to cohort
Record W4410088019 · doi:10.1371/journal.pone.0321032

RETRACTED: Cardiovascular and mortality outcomes of DPP-4 inhibitors vs. sulfonylureas as metformin add-on therapy in patients with type 2 diabetes: A systematic review and meta-analysis

2025· review· en· W4410088019 on OpenAlexaboutno aff
Rumina Hasan, Uliana Y. Chugaeva, Mahdi Mohammadian, Somayeh Zamanifard, Abdollah Mohammadian-Hafshejani

Post-publication record

NatureRetraction
ReasonBreach of Policy by Author;Concerns/Issues about Article;Investigation by Journal/Publisher;Objections by Author(s);Unreliable Results and/or Conclusions;
Date12/17/2025 0:00
Flagged by OpenAlex?Yes

Source: Retraction Watch, joined by DOI. OpenAlex records retraction as is_retracted, a boolean over a state space with at least four values, so it cannot express an expression of concern, a correction or a reinstatement; it reports them as false, which reads as “fine”.

Bibliographic record

VenuePLoS ONE · 2025
Typereview
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsnot available
Fundersnot available
KeywordsMetforminMedicineType 2 diabetesInternal medicineMeta-analysisDiabetes mellitusRelative riskJadad scaleSitagliptinVildagliptinAdverse effectConfidence intervalEndocrinologyCochrane LibraryInsulin

Abstract

fetched live from OpenAlex

BACKGROUND: Type 2 diabetes significantly increase the risk of cardiovascular disease and mortality. This systematic review and meta-analysis compared cardiovascular and mortality outcomes in type 2 diabetes patients receiving dipeptidyl peptidase-4 inhibitors (DPP-4is) plus metformin versus sulfonylureas (SUs) plus metformin as add-on therapy. METHODS: PubMed, Web of Science, Cochrane Central Register of Controlled Trials, Embase, Google Scholar, and Scopus were searched through January 1, 2025, for studies comparing DPP-4is plus metformin versus SUs plus metformin in type 2 diabetes patients. Outcomes of interest were major adverse cardiovascular events and all-cause mortality. Heterogeneity was assessed using Cochran's Q test and I2 statistic. Publication bias was evaluated with Begg's and Egger's tests. Study quality was assessed with the Jadad scale (for randomized controlled trials) and the Newcastle-Ottawa Scale (for observational studies). RESULTS: Twenty-seven studies (2012-2024), encompassing 1,505,821 participants, were included in the analysis. Major adverse cardiovascular events were reported in 21 studies, and all-cause mortality data were available from 19 studies. Meta-analysis revealed a significantly lower risk of both major adverse cardiovascular events (risk ratio [RR]: 0.79; 95% confidence interval [CI]: 0.73-0.84; p < 0.001) and all-cause mortality (RR: 0.79; 95% CI: 0.71-0.88; p < 0.001) in patients with diabetes treated with DPP-4 inhibitors plus metformin compared to those treated with SUs plus metformin. No publication bias was detected. CONCLUSION: In type 2 diabetes patients treated with metformin, adding a DPP-4is is associated with significantly lower risks of major adverse cardiovascular events and all-cause mortality compared to adding an SUs. These findings underscore the potential cardiovascular benefits of DPP-4is and their role in improving patient outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.055
metaresearch head score (Gemma)0.136
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesResearch integrity
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Meta-analysis · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.996
Threshold uncertainty score0.291

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0550.136
Meta-epidemiology (narrow)0.0030.002
Meta-epidemiology (broad)0.0130.022
Bibliometrics0.0070.008
Science and technology studies0.0010.001
Scholarly communication0.0050.005
Open science0.0050.003
Research integrity0.0040.004
Insufficient payload (model declined to judge)0.0110.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.078
GPT teacher head0.294
Teacher spread0.217 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designMeta-analysis
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuePLoS ONE→Same topicDiabetes Treatment and Management→French-language works237,207→